MYC amplification in breast cancer: A chromogenic in situ hybridisation study

Journal of Clinical Pathology

Volumn 60, Issue 9, 2007, Pages 1017-1023

  Rodriguez Pinilla, S Maria ^a   Jones, Robin L ^a   Lambros, Maryou B K ^a   Arriola, Edurne ^a   Savage, Kay ^a   James, Michelle ^a   Pinder, Sarah E ^b   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 8; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE AMPLIFICATION; GENE NUMBER; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MOLECULAR PROBE; MULTIVARIATE ANALYSIS; MUTATION; ONCOGENE C MYC; ONCOGENE MYC; OVERALL SURVIVAL; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TISSUE MICROARRAY; TUMOR CELL; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOGENIC COMPOUNDS; FEMALE; GENE AMPLIFICATION; GENES, MYC; HUMANS; MASTECTOMY; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 34548833289     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.043869     Document Type: Article

References (40)

1. Deming SL, Nass SJ, Dickson RB, et al. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688-95.
2. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000;7:143-64.
3. Patel JH, Loboda AP, Showe MK, et al. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 2004;4:562-8.
4. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76.
5. Blancato J, Singh B, Liu A, et al. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 2004;90:1612-9.
6. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997;10:720-7.
7. Robanus-Maandag EC, Bosch CA, Kristel PM, et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 2003;201:75-82.
8. Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001;81:1545-51.
9. Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 2001;14:1030-5.
10. Shimada M, Imura J, Kozaki T, et al. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. Oncol Rep 2005;13:633-41.
11. Visscher DW, Wallis T, Awussah S, et al. Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics. Genes Chromosomes Cancer 1997;18:1-7.
12. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
13. Aulmann S, Adler N, Rom J, et al. c-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol 2006;59:424-8.
14. Glockner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-26.
15. Adem C, Soderberg CL, Hafner K, et al. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 2004;41:1-11.
16. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004;10:499-507.
17. Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno- Bueno G, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype. An immunohistochemical and gene amplification study. Am J Surg Pathol 2007;31:501-8.
18. Schmitt FC, Reis-Filho JS. c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant? Breast Cancer Res 2003;5:188-91.
19. Janocko LE, Brown KA, Smith CA, et al. Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 2001;46:136-49.
20. Palacios J, Honrado E, Osorio A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005;90:5-14.
21. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
22. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
23. Turner N, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25:5846-53.
24. Turner N, Reis-Filho JS, Russel AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32.
25. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5.
26. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
27. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006;19:999-1009.
28. Reis-Filho JS, Steele D, Di Palma S, et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol 2006;19:307-19.
29. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 1991;19:403- 10.
30. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
31. Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86:398-408.
32. Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005;207:1-13.
33. Schlotter CM, Vogt U, Bosse U, et al. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003;5:R30-6.
34. Kim C, Bryant J, Horne Z, et al. Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo (abstract). Breast Cancer Res Treat 2005;94:46.
35. Borg A, Baldetorp B, Ferno M, et al. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 1992;51:687-91.
36. Mertens F, Johansson B, Hoglund M, et al. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 1997;57:2765-80.
37. Adler AS, Lin M, Horlings H, et al. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 2006;38:421-30.
38. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
39. Adler AS, Chang HY. From description to causality: mechanisms of gene expression signatures in cancer. Cell Cycle 2006;5:1148-51.
40. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-43.